A Professional Service Provider for the Pharma Industry
It started all so well with fanfare and great expectations. Fifteen years ago, the 10 x ’20 initiative got underway. Its goals were spelled out clearly: To ‘Pursue a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 ’[3]. It Continue reading The 10 x ’20 Initiative – A Retrospective
Today we discuss the group of BAFF/APRIL inhibitors, specifically the three TACI mAb constructs that are currently in development. They were tested in a broad gamut of B-cell indications but failed to show efficacy in many. So far, consistent clinical Continue reading BAFF / APRIL Inhibitors Homing in on IgAN
Companies can stop studies before reaching projected enrollment numbers. It could be a decision based on a planned interim analysis (IA) or it could be for ‘administrative’ reasons. The latter may not indicate that a company has fallen on hard Continue reading THE UTILITY OF FUTILITY
Sulopenem / ORLYNVAH approved for uUTI When Iterum, a Pfizer spin-off of sorts, took over sulopenem development in 2015, there was still hope for approvals of this drug in multiple indications such as uUTI, cUTI, cIAI and even CABP. Ten Continue reading Sulopenem uUTI – Does It Suffice?
With the average number of 6-7 authors per (clinical) publication and an increasing trend for multi-authored articles there are now plenty of opportunities for industrious clinicians to publish. Here are just a few examples of super-achievers from the Infectious Disease Continue reading PUBLICATION OVERACHIEVERS